ClinicalTrials.gg
CompletedNCT05866354Updated Nov 27, 2023

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

A Phase 1 interventional study of Tisotumab Vedotin in Solid Malignancies, sponsored by Zai Lab (Shanghai) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
366th of 401
19 · median 90
Started
2023
with 40 others
Phase 1
93 of 485
47 open now
Registered
279th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 366th largest by enrollment of the 401 interventional ones that give a count, is one of 41 that started in 2023, is one of 93 in phase 1, and was the 279th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test in Chinese Subjects with Metastatic or Recurrent Solid Malignancies. The main questions it aims to answer are:

  • How is the PK of tisotumab vedotin?
  • How is the immunogenicity of tisotumab vedotin?
  • How is the safety and tolerability of tisotumab vedotin?
  • How is the clinical efficacy of tisotumab vedotin? Participants will receive 2.0 mg/kg tisotumab vedotin (up to a maximum of 200 mg in subjects ≥ 100 kg) as a 30-minute IV infusion 1Q3W with the aim to characterize the PK profiles and to evaluate immunogenicity, safety, and tolerability of tisotumab vedotin in the Chinese population.

Subjects will receive study treatment until disease progression or any other discontinuation criteria are met, whichever occurs first. Subjects will undergo an end of treatment (EOT) visit 30 days (± 5 days) after the last dose of study treatment or within 7 days after treatment discontinuation has been decided, whichever occurs later.

Read the detailed description

This is an open-label, phase 1, PK trial of intravenous tisotumab vedotin in Chinese subjects with recurrent or metastatic solid tumors who have failed on previous standard systemic therapy. The screening period will be up to 28 days, after which eligible subjects will receive 2.0 mg/kg tisotumab vedotin (up to a maximum of 200 mg in subjects ≥ 100 kg) as a 30-minute IV infusion 1Q3W with the aim to characterize the PK profiles and to evaluate immunogenicity, safety, and tolerability of tisotumab vedotin in the Chinese population.

Subjects will receive study treatment until disease progression or any other discontinuation criteria are met, whichever occurs first. Subjects will undergo an end of treatment (EOT) visit 30 days (± 5 days) after the last dose of study treatment or within 7 days after treatment discontinuation has been decided, whichever occurs later.

Blood samples for the assessment of tisotumab vedotin concentrations and antidrug antibody (ADA) will be drawn in accordance with the PK and ADA collection schedule. Three different PK analytes will be measured: 1) tisotumab vedotin (conjugated antibody only), 2) total antibody (ie, conjugated and unconjugated antibody), and 3) free MMAE. PK parameters to be estimated will include, but are not limited to, AUC, Cmax, time to maximum concentration (Tmax), apparent terminal half-life (t1/2), and trough concentration (Ctrough).

Safety and tolerability will be evaluated based on TEAEs, clinical safety assessments and clinical laboratory assessments. Ocular AEs are a known safety risk of tisotumab vedotin treatment. Therefore, the eye care plan will be implemented for all subjects enrolled in this trial.

Efficacy assessments will include confirmed ORR assessed by the investigator, primarily based on the enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans performed at protocol-specified time points. The RECIST v1.1 criteria will be used for response evaluation. After discontinuation of study treatment, tumor assessments may or may not be performed at the discretion of the investigator.

At the end of study (EOS), sponsor will ensure provision of continued tisotumab vedotin to subjects with clinical benefit defined as stable disease (SD) or better, until criteria of treatment discontinuation are met.

03

Conditions studied

  • Solid Malignancies

Browse trials for

Keywords

  • Metastatic or Recurrent Solid Malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Must sign an form (ICF) .
  3. Must have recurrent or solid tumors and have failed on previous standard systemic therapy.
  4. Has (ECOG) performance status of 0 or 1.
  5. Has of at least 3 months.
  6. Must demonstrate acceptable screening laboratory values.
  7. Female subjects must agree not to breastfeed or donate ova. A male subject who is sexually active with a female partner of and has not had a vasectomy must agree to use a barrier method of (eg, condom with spermicide), and all men must also not donate sperm during the trial and for 6 months after receiving the last dose of tisotumab vedotin.
  8. Any other toxicity caused by previous treatment should have recovered to ≤ grade 1 or baseline level, except ≤ CTCAE grade 2 alopecia.

Exclusion criteria

Exclusion Criteria:

  1. Has bleeding issues or risks:
  2. Has cardiovascular issues or risks:
  3. Central nervous system (CNS): any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke ( > 1 month prior to screening is allowed).
  4. Ophthalmological: active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (eg, Wagner syndrome, atopic keratoconjunctivitis, disease affecting the eyes), and subjects with penetrating ocular transplants are ineligible. Cataracts alone is not an exclusion criterion.
  5. Surgery/procedures: major surgery within 4 weeks or minor surgery within 7 days prior to the first study treatment administration.
  6. Peripheral neuropathy ≥ grade 2.
  7. Any prior treatment with MMAE-derived drugs.
  8. Has a diagnosis of immunodeficiency or is receiving systemic therapy (dose exceeding 10 mg daily of prednisone or equivalent) or any other form of therapy within 7 days prior to the first dose of tisotumab vedotin.
  9. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Interventions

  • Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.

06

What researchers measure

Primary outcomes

  1. PK parameter AUC of tisotumab vedotin

    To assess PK of tisotumab vedotin.PK parameters to be estimated will include area under the concentration-time curve (AUC).

    Time frame: At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year.

  2. PK parameter Cmax of tisotumab vedotin

    To assess PK of tisotumab vedotin.PK parameters to be estimated will include maximum concentration (Cmax).

    Time frame: At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year.

  3. PK parameter Tmax of tisotumab vedotin

    To assess PK of tisotumab vedotin.PK parameters to be estimated will include time to maximum concentration (Tmax).

    Time frame: At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year.

  4. PK parameter t 1/2 of tisotumab vedotin

    To assess PK of tisotumab vedotin.PK parameters to be estimated will include apparent terminal half-life (t 1/2).

    Time frame: At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year.

  5. PK parameter C trough of tisotumab vedotin

    To assess PK of tisotumab vedotin.PK parameters to be estimated will include trough concentration (C trough).

    Time frame: At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year.

Secondary outcomes

  1. Immunogenicity of tisotumab vedotin.

    Anti-drug antibodies (ADAs) against tisotumab vedotin.

    Time frame: At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year.

  2. Treatment-emergent adverse events (TEAEs) of tisotumab vedotin.

    A TEAE is defined as a newly occurring or worsening AE from the first dose of study treatment to 30 days after the last dose of study treatment or initiation of new antitumor activities, whichever occurs first.

    Time frame: Through study completion, an average of 1 year.

Other outcomes

  1. Objective response rate (ORR) of tisotumab vedotin.

    Confirmed objective response rate (ORR) assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Through study completion, an average of 1 year.

07

Study locations

1 site
  • Jinan Central Hospital
    Jinan, Shangdong 250013, China
08

References and documents

Individual participant data

Plan to share: No — When the study close, the IPD will share to other researchers per the requirement from Zailab.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Nov 2023, 4 months.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 4 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 19, 2023
StartActual
Jun 16, 2023
Primary completionActual
Nov 2, 2023
CompletionActual
Nov 2, 2023
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05866354
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Jun 16, 2023
Primary completion
Nov 2, 2023
Completion
Nov 2, 2023
Last update
Nov 27, 2023

Study contacts

Rutie Yin, Dr
principal investigator · West China Second University Hospital
Guiling Li, Dr
principal investigator · Wuhan Union Hospital, China
Bingzhong Zhang, Dr
principal investigator · Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Qing Wen, Dr
principal investigator · Jinan Central Hospital
Meili Sun, Dr
principal investigator · Jinan Central Hospital
Jianhua Shi, Dr
principal investigator · Linyi Cancer Hospital
Dongqing Lv, Dr
principal investigator · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Tienan Yi, Dr
principal investigator · Xiangyang Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion